Evidence map›Paper›PMID 30557324›Full record

ArticlePloS one2018

Hepatitis E virus seroprevalence and determinants in various study populations in the Netherlands.

C J Alberts, M F Schim van der Loeff, S Sadik, F R Zuure, E J A J Beune, M Prins, M B Snijder, S M Bruisten

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Increasing trends in hepatitis E hospitalisations in Spain, 1997 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  4. Review
  5. Article
  6. Risk assessment of hepatitis E transmission through tissue allografts.World journal of gastrointestinal pathophysiology · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Assessment of hepatitis E seropositivity among HIV-infected patients in Bulgaria.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C J AlbertsDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.
M F Schim van der LoeffDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.ORCID 0000-0002-4903-7002
S SadikDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.
F R ZuureDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.
E J A J BeuneDepartment of Public Health, Academic Medical Centre (AMC), University of Amsterdam, Amsterdam, the Netherlands.
M PrinsDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.
M B SnijderDepartment of Public Health, Academic Medical Centre (AMC), University of Amsterdam, Amsterdam, the Netherlands.
S M BruistenDepartment of Infectious Diseases, Public Health Service Amsterdam (GGD), Amsterdam, the Netherlands.ORCID 0000-0003-4897-4261

Funding

ZonMw 200500003
6 · The paper itself

Abstract

backgroundThe epidemiology of hepatitis E virus (HEV) is not fully understood. In this study, we assessed putative risk factors for HEV seropositivity in various study populations in the Netherlands.

methodsData and samples from five different study populations were analysed: (A) blood donors (n = 5,239), (B) adults reporting a vegetarian life style since the age of 12 years (n = 231), (C) residents of Amsterdam, the Netherlands, with different ethnic backgrounds (n = 1,198), (D) men who have sex with men (MSM) (HIV positive and HIV negative) (n = 197), and (E) persons who use drugs (PWUD) (HIV positive and HIV negative) (n = 200). Anti-HEV immunoglobulin M (IgM) and immunoglobulin G (IgG) testing was performed using ELISA test (Wantai).

resultsHEV IgM seroprevalence was low across all study populations (<1% to 8%). The age and gender-adjusted HEV IgG seroprevalence was 24% among blood donors (reference group) and 9% among the vegetarian group (adjusted Relative Risk [aRR]:0.36, 95%CI:0.23-0.57). Among participants of different ethnic backgrounds, the adjusted HEV IgG seroprevalence was 16% among participants with a Dutch origin (aRR:0.64, 95%CI:0.40-1.02), 2% among South-Asian Surinamese (aRR:0.07, 95%CI:0.02-0.29), 3% among African Surinamese (aRR:0.11, 95%CI:0.04-0.34), 34% among Ghanaian (aRR:1.53, 95%CI:1.15-2.03), 19% among Moroccan (aRR:0.75, 95%CI:0.49-1.14), and 5% among Turkish (aRR:0.18, 95%CI:0.08-0.44) origin participants. First generation Moroccans had a higher risk for being IgG HEV seropositive compared to second generation Moroccan migrants. The statistical power to perform these analyses in the other ethnic groups was too low. In the MSM group the IgG HEV seroprevalence was 24% (aRR:0.99, 95%CI:0.76-1.29), and among PWUD it was 28% (aRR:1.19, 95%CI:0.90-1.58). The number of sexual partners in the preceding six months was not significantly associated with IgG HEV seropositivity in MSM. The association between HIV status and HEV seropositivity was significant in PWUD, yet absent in MSM. HIV viral load and CD4 cell count were not associated with HEV seropositivity in HIV positive MSM and PWUD.

conclusionsVegetarians were significantly less often HEV seropositive. Ethnic origin influenced the risk for being IgG HEV seropositive. MSM and PWUD were not at higher risk for being IgG HEV seropositive than blood donors.

Indexed as

AdultAgedBlood DonorsEmigrants and ImmigrantsFemaleHepatitis AntibodiesHepatitis EHepatitis E virusHomosexuality, MaleHumansImmunoglobulin GImmunoglobulin MLife StyleMaleMiddle AgedNetherlandsHepatitis AntibodiesImmunoglobulin GImmunoglobulin M

Identifiers

PMID30557324
PMCPMC6296558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.